| Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Investors - Lead Plaintiff Deadline on July 14, 2025 |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=148926&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 16:30:00 |
Czytaj oryginał (ang.) |
| Rosen Law Firm Urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Stockholders With Large Losses to Contact the Firm for Information About Their Rights |
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”). Iovance is a commercial stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating th. |
businesswire.com |
2025-05-16 15:35:00 |
Czytaj oryginał (ang.) |
| Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA) |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=148912&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 15:15:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Iovance Biotherapeutics, Inc. (IOVA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm |
ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Iovance's business, operations, and prospects, including allegations that: (1) new Authorized Treatment Centers (“ATCs”) were experiencing longer timelines to begin treating patients with Amtagvi; (2) Iovance's sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs; and (3) the foregoing dynamics led to higher costs and lower revenue because ATCs could not keep pace with manufactured product. |
globenewswire.com |
2025-05-16 15:01:00 |
Czytaj oryginał (ang.) |
| IOVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-05-16 15:00:00 |
Czytaj oryginał (ang.) |
| Join Class Action to Recover Losses from Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025 |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=148904&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 14:15:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Iovance Biotherapeutics, Inc. (IOVA) And Encourages Stockholders to Reach Out |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA). Investors who purchased Iovance securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IOVA. |
accessnewswire.com |
2025-05-16 14:00:00 |
Czytaj oryginał (ang.) |
| Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA) |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=148869&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 13:15:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-16 13:00:00 |
Czytaj oryginał (ang.) |
| IOVA CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Iovance Biotherapeutics, Inc. |
LOS ANGELES--(BUSINESS WIRE)--IOVA CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Iovance Biotherapeutics, Inc. |
businesswire.com |
2025-05-16 06:18:00 |
Czytaj oryginał (ang.) |
| IOVA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Iovance Biotherapeutics, Inc. Investors |
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Farberov v. Iovance Biotherapeutics, Inc., et al., Case No. 25-cv-4199, on behalf of persons and entities that purchased or otherwise acquired Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Per. |
businesswire.com |
2025-05-16 04:10:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Iovance Biotherapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of July 14, 2025 |
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) between August 8, 2024, to May 8, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Karthik Trichur Sundaram v. |
globenewswire.com |
2025-05-15 20:41:00 |
Czytaj oryginał (ang.) |
| Fraud Investigation: Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Shareholders |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IOVA) concerning possible violations of federal securities laws. On May 8, 2025, after the market closed, Iovance issued their first quarter fiscal 2025 results well below expectations, announcing a loss of 36 cents per share on revenue of $49 million. |
accessnewswire.com |
2025-05-15 19:00:00 |
Czytaj oryginał (ang.) |
| Lovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman |
IOVA Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / May 15, 2025 / In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the San Carlos-based cell therapy pioneer reported a first-quarter revenue miss that sharply contradicted earlier upbeat assurances from management. Hagens Berman is now investigating whether Iovance violated U.S. securities laws and urges Iovance investors who suffered substantial losses to submit your losses now. |
accessnewswire.com |
2025-05-15 18:30:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - IOVA |
LOS ANGELES--(BUSINESS WIRE)--Iovance Biotherapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - IOVA. |
businesswire.com |
2025-05-15 16:10:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. (IOVA) Over Potential Securities Fraud Allegations |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IOVA) concerning possible violations of federal securities laws. On May 8, 2025, after the market closed, Iovance issued their first quarter fiscal 2025 results well below expectations, announcing a loss of 36 cents per share on revenue of $49 million. |
accessnewswire.com |
2025-05-15 14:30:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Iovance Biotherapeutics, Inc. (IOVA) And Encourages Stockholders to Connect |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA). Investors who purchased Iovance securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IOVA. |
accessnewswire.com |
2025-05-15 14:00:00 |
Czytaj oryginał (ang.) |
| Is This Beaten-Down Stock a Buy Near Its 52-Week Low? |
Penny stocks -- companies with shares trading at around $5 or even less apiece -- usually carry above-average risk. However, there may be hidden gems among them: companies with attractive prospects that continue to be ignored by most investors. |
fool.com |
2025-05-15 09:14:00 |
Czytaj oryginał (ang.) |
| IOVA ALERT: Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. for Possible Securities Fraud Violations |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IOVA) concerning possible violations of federal securities laws. On May 8, 2025, after the market closed, Iovance issued their first quarter fiscal 2025 results well below expectations, announcing a loss of 36 cents per share on revenue of $49 million. |
accessnewswire.com |
2025-05-14 21:15:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% – Hagens Berman |
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the San Carlos-based cell therapy pioneer reported a first-quarter revenue miss that sharply contradicted earlier upbeat assurances from management. |
globenewswire.com |
2025-05-14 20:47:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates |
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.45 per share a year ago. |
zacks.com |
2025-02-27 20:25:27 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024 |
Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M |
globenewswire.com |
2025-02-27 18:01:00 |
Czytaj oryginał (ang.) |
| What's in Store for These 5 Biotech Stocks This Earnings Season? |
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025. |
zacks.com |
2025-02-24 13:30:24 |
Czytaj oryginał (ang.) |
| Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know |
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-20 13:05:31 |
Czytaj oryginał (ang.) |
| My 3 Favorite Stocks to Buy Right Now |
If you're struggling to find compelling prospects for your portfolio right now, you're not alone. The market's usual favorites are seemingly out of favor. |
fool.com |
2025-02-20 09:30:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025 |
SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full year 2024 financial results and corporate updates on Thursday, February 27, 2025. |
globenewswire.com |
2025-02-18 18:01:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 10, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of up to 305,000 shares of Iovance's common stock to Daniel Kirby, the Company's new Chief Commercial Officer. |
globenewswire.com |
2025-02-12 19:30:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer |
SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today. |
globenewswire.com |
2025-02-10 09:00:00 |
Czytaj oryginał (ang.) |
| What's Wrong With Iovance Biotherapeutics Stock? |
It was about a year ago that shares of Iovance Biotherapeutics (IOVA -1.94%) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel) as a treatment option for patients with unresectable or metastatic melanoma. |
fool.com |
2025-01-30 09:30:00 |
Czytaj oryginał (ang.) |
| Where Will Iovance Biotherapeutics Be in 5 Years? |
Iovance Biotherapeutics (IOVA -0.96%), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the company has encountered some success, including a crucial regulatory approval coming down last year, that hasn't been enough to seduce investors. |
fool.com |
2025-01-29 10:30:00 |
Czytaj oryginał (ang.) |
| Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts |
If you're looking for an under-the-radar stock that could deliver enormous gains in a defined time frame, the biopharmaceutical industry has you covered. Hardly a week goes by without clinical trial results or a regulatory decision that produces dramatic market movements. |
fool.com |
2025-01-27 06:31:00 |
Czytaj oryginał (ang.) |
| 3 Stocks That Could Turn $1,000 Into $5,000 by 2030 |
Finding the market's highest-growth prospects at any given time isn't terribly tough to do. Finding stocks capable of quintupling in value over the course of the coming five years, however, is a different story. |
fool.com |
2025-01-18 20:50:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 224,550 shares of Iovance's common stock to forty-one new, non-executive employees. |
globenewswire.com |
2025-01-17 19:00:00 |
Czytaj oryginał (ang.) |
| Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 |
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions. |
seekingalpha.com |
2025-01-13 20:10:02 |
Czytaj oryginał (ang.) |
| 3 Mid-Cap Stocks That Could Take Off in 2025 |
Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2 billion and $10 billion. |
fool.com |
2025-01-09 06:20:00 |
Czytaj oryginał (ang.) |
| Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today |
Now this is a fine way for a stock to greet the new year. On the back of a glowing analyst recommendation, Iovance Biotherapeutics's (IOVA 5.27%) shares closed Thursday more than 5% higher in price. |
fool.com |
2025-01-02 21:03:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 19, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 203,980 shares of Iovance's common stock to forty-eight new, non-executive employees. |
globenewswire.com |
2024-12-20 19:00:00 |
Czytaj oryginał (ang.) |
| If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These |
Investors are fortunate to have access to a universe of stocks that they can buy or sell at any given time. Sometimes, however, limiting your options can be a powerful exercise. |
fool.com |
2024-12-19 06:02:00 |
Czytaj oryginał (ang.) |
| 2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? |
Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025. |
fool.com |
2024-12-17 07:29:00 |
Czytaj oryginał (ang.) |
| Prediction: This Stock Will Beat the Market in 2025 |
It hasn't been a great year for Iovance Biotherapeutics (IOVA -1.40%), an innovative mid-cap biotech company. The drugmaker's shares have significantly lagged the market -- advancing only about 5% so far this year. |
fool.com |
2024-12-12 12:00:00 |
Czytaj oryginał (ang.) |
| 3 Monster Stocks to Hold for the Next 10 Years |
It's usually not difficult to find a compelling growth stock to step into. Choosing a growth stock you're confident holding onto for a decade or more, however, is a different story. |
fool.com |
2024-12-07 13:08:00 |
Czytaj oryginał (ang.) |
| Is Iovance Biotherapeutics Stock a Millionaire Maker? |
The biotech industry has been described as the Wild West of the stock market. Although some companies manage to develop and commercialize a life-changing therapeutic, countless more start-ups inevitably fail. |
fool.com |
2024-11-27 08:30:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer |
SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Raj Puri, M.D., Ph.D. has been promoted to the newly created role of Chief Regulatory Officer. Dr. Puri joined Iovance in March 2022 as Executive Vice President, Regulatory Strategy and Translational Medicine. |
globenewswire.com |
2024-11-26 18:01:00 |
Czytaj oryginał (ang.) |
| Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back |
As the rising star of cell therapy biotechs, Iovance Biotherapeutics (IOVA 3.76%) is a hot stock that's capturing a lot of attention, and for good reason. Iovance's one-of-a-kind medicine is already selling like hotcakes, and there's reason to believe that plenty more growth is on the way. |
fool.com |
2024-11-23 13:35:00 |
Czytaj oryginał (ang.) |
| 2 Innovative Stocks That Could Deliver Outsize Returns |
2 Innovative Stocks That Could Deliver Outsize Returns |
fool.com |
2024-11-22 12:00:00 |
Czytaj oryginał (ang.) |
| 2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More |
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More |
fool.com |
2024-11-16 08:00:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity |
Iovance Biotherapeutics' Q3 earnings outperformed expectations, with $58.6m in revenue, but shares fell due to high market expectations and competition concerns. Amtagvi, Iovance's lead drug, shows strong commercial potential with 2025 revenue guidance of $450-$475m and significant opportunities in melanoma and other cancers including NSCLC. Despite high cash burn and competition, Iovance's growth in revenue, reimbursement, and treatment centers suggests a “buy the dip” opportunity for risk-tolerant investors. |
seekingalpha.com |
2024-11-11 16:16:04 |
Czytaj oryginał (ang.) |
| IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line |
Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025. |
zacks.com |
2024-11-08 13:15:32 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript |
Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-07 22:55:53 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates |
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago. |
zacks.com |
2024-11-07 20:46:28 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 |
Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 Enrollment Accelerating in IOV-LUN-202 Registrational Phase 2 Trial in Post-anti-PD-1 NSCLC SAN CARLOS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported third quarter and year to date 2024 financial results and corporate updates. |
globenewswire.com |
2024-11-07 18:01:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 |
SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year to date 2024 financial results on Thursday, November 7, 2024. |
globenewswire.com |
2024-10-31 18:01:00 |
Czytaj oryginał (ang.) |
| Why Iovance Biotherapeutics Stock Triumphed on Thursday |
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout. |
fool.com |
2024-10-24 22:01:02 |
Czytaj oryginał (ang.) |
| Is Iovance Biotherapeutics Stock a Buy? |
The biotech is making important breakthroughs, but is that enough? |
fool.com |
2024-10-04 12:30:00 |
Czytaj oryginał (ang.) |
| Iovance Biotherapeutics: Moving To The Next Phase |
Iovance Biotherapeutics' Amtagvi has gained rapid market traction post-FDA approval, with strong Q3 performance and promising revenue projections for 2024 and beyond. The company's growth prospects are bolstered by potential regulatory approvals in international markets and ongoing trials in other cancer types, including NSCLC. Despite the positive outlook, risks include market penetration challenges, regulatory hurdles, competition, and financial sustainability concerns due to ongoing cash burn. |
seekingalpha.com |
2024-10-03 18:43:36 |
Czytaj oryginał (ang.) |